PeptidesEvidence ReviewAug 2026

Best Peptides for Hair Growth in 2026

For each peptide studied on hair, this page reports the paper behind it: who or what was studied, what was measured, what the result was. Every citation was retrieved through NCBI E-utilities on 9 August 2026. Some of the hair data came from people, some from human tissue in culture, and several results were measured in mice, so the population column is where each finding is pinned to what it was actually tested on. Minoxidil and finasteride trials sit in the table as comparators, not as peptides.

Men in the GHK peptide trial (PMID 27489425)

393

Men in the minoxidil comparator trial (PMID 12196747)

1553

Men in the finasteride comparator trial (PMID 9777765)

The Studies

One row per study, not one per compound. A compound studied more than once gets more than one row, because those papers asked different questions in different populations. Read the population and design columns before the result, because a follicle in a dish, a mouse and a man are three different tests.

Compound	Population (n)	What was measured	Result	Design	PMID
Copper tripeptide (AHK-Cu)	Human hair follicles in organ culture and cultured human dermal papilla cells (n not stated in the abstract)	Hair follicle elongation ex vivo, dermal papilla cell proliferation, and apoptosis markers (Bcl-2/Bax ratio, cleaved caspase-3, PARP)	AHK-Cu at 10^-12 to 10^-9 M stimulated follicle elongation and dermal papilla cell proliferation; the Bcl-2/Bax ratio rose and cleaved caspase-3 and PARP fell; the drop in apoptotic cells was not statistically significant	Ex vivo human hair follicle organ culture and in vitro cell study	17703734
GHK peptide with 5-aminolevulinic acid (ALAVAX)	45 men with male pattern hair loss, randomised across three arms	Total hair count, hair length and hair thickness over 6 months	Hair count rose 52.6 on the 100 mg/mL complex (P below .05) and 71.5 on the 50 mg/mL complex (P below .05) versus 9.6 on placebo; hair length and thickness did not differ significantly between the groups	Randomised placebo-controlled trial, three arms, topical once daily for 6 months	27489425
Copper tripeptide-1 topical serum (multi-ingredient scalp regimen)	Adults with mild to moderate dandruff and scalp flaking (n not stated in the abstract)	Adherent Scalp Flaking Score, scalp hydration, and instrument-measured hair density and hair thickness over 15 days	By day 15 hair density rose 12.48 percent and hair thickness 25.36 percent (both P below .0001), and adherent scalp flaking fell 61.24 percent (P below .0001)	Prospective open-label single-arm interventional study, no control group	39449909
PTD-DBM (CXXC5-Dishevelled competing peptide)	CXXC5 knockout and wild-type mice, with human balding-scalp tissue and cultured human dermal papilla cells (n not stated in the abstract)	Hair regrowth rate after depilation, wound-induced hair follicle neogenesis, and dermal papilla cell proliferation and alkaline phosphatase	Disrupting the CXXC5-Dishevelled interaction with the competitor peptide activated Wnt/beta-catenin signalling and accelerated hair regrowth and wound-induced follicle neogenesis in mice; CXXC5 was raised in human balding scalp tissue	Mouse study with human tissue and cell work	28595998
PTD-DBM (CXXC5-Dishevelled competing peptide)	Mice in DHT-induced and prostaglandin D2-induced hair-loss models and a wound-induced hair neogenesis model (n not stated in the abstract)	Hair loss and neogenic hair growth after DHT or prostaglandin D2 challenge	DHT-induced and prostaglandin D2-induced hair loss, and the suppression of neogenic hair growth, were alleviated by PTD-DBM treatment or Cxxc5 knockout	Mouse model study	36831222
Thymosin beta-4	Transgenic mice overexpressing thymosin beta-4 in the epidermis, global knockout mice, and controls (n not stated in the abstract)	Hair re-growth speed after depilation, hair shaft and follicle numbers, VEGF, and P38/ERK/AKT signalling	Re-growth was faster in overexpressing mice and slower in knockout mice; overexpressing mice had more hair shafts and follicles and higher VEGF expression	Transgenic mouse study	26083021
Finasteride, oral (comparator)	1553 men aged 18 to 41 with male pattern hair loss	Scalp hair count in a 5.1 cm2 vertex area, plus patient, investigator and photographic assessment	Finasteride 1 mg daily increased hair count by 107 hairs at 1 year and 138 at 2 years versus placebo (P below .001); baseline was 876 hairs; placebo lost hair progressively	Two 1-year randomised double-blind placebo-controlled trials with a blinded second-year extension	9777765
Minoxidil, topical (comparator)	393 men aged 18 to 49 with androgenetic alopecia (5 percent n=157, 2 percent n=158, placebo n=78)	Nonvellus target-area hair count and patient and investigator scalp-coverage ratings over 48 weeks	5 percent minoxidil twice daily beat 2 percent and placebo on nonvellus hair count, with about 45 percent more regrowth than 2 percent at week 48; pruritus and local irritation were more common on 5 percent	Randomised double-blind placebo-controlled multicentre trial, 48 weeks	12196747

Copper Peptide Studies

The copper peptide studies sit at different distances from a person. The follicle work was done in human tissue in a dish: AHK-Cu, an alanyl-histidyl-lysine copper tripeptide, stimulated the elongation of human hair follicles in organ culture and the proliferation of dermal papilla cells, while shifting apoptosis markers, at concentrations of 10^-12 to 10^-9 M (PMID 17703734). That is a laboratory result in cultured tissue, not a measurement of hair on a head.

A placebo-controlled human study paired a GHK peptide with 5-aminolevulinic acid. In 45 men with male pattern hair loss, hair count rose 52.6 on the stronger complex and 71.5 on the weaker one against 9.6 on placebo over 6 months, while hair length and thickness did not separate (PMID 27489425). Because the active was a GHK peptide combined with 5-ALA, the result belongs to that combination rather than to a bare peptide. Compound background sits on the GHK-Cu page and the topical GHK-Cu page.

A third study tracked a copper tripeptide-1 scalp serum inside a multi-ingredient regimen with a hydroxy acid scrub. Over 15 days in adults with mild to moderate dandruff, instrument readings put hair density up 12.48 percent and hair thickness up 25.36 percent while adherent flaking fell 61.24 percent (PMID 39449909). It was open-label with no control group and several actives in the serum, so the hair figures cannot be pinned to the copper peptide alone. What a label claims versus what a vial holds is a separate question, covered on the COA verification guide.

PTD-DBM And Wnt Signalling

PTD-DBM is a peptide built to block CXXC5 from binding Dishevelled, which lifts a brake on the Wnt/beta-catenin pathway used in hair follicle growth. In the origin study, the competing peptide activated that pathway and accelerated hair regrowth and wound-induced follicle neogenesis in mice, alongside a finding that CXXC5 was raised in human balding scalp tissue and cultured dermal papilla cells (PMID 28595998). A later mouse study tied the same CXXC5 axis to hair loss driven by DHT and prostaglandin D2, and reported that PTD-DBM treatment or Cxxc5 knockout alleviated it (PMID 36831222). Both results were measured in mice, with supporting human cell and tissue work, and neither is a hair-count result in people. The BPC-157 page covers a different repair peptide for reference.

Thymosin Beta-4

Thymosin beta-4 was studied through genetics rather than a topical. Mice engineered to overexpress thymosin beta-4 in the epidermis regrew hair faster after depilation and carried more hair shafts and follicles, while global knockout mice regrew slower and had fewer shafts, with VEGF and P38/ERK/AKT signalling moving alongside (PMID 26083021). That is a transgenic mouse result about a signalling molecule, and it describes mice. The molecule also appears in injury and wound work; background sits on the TB-500 page and the injury healing guide.

Minoxidil And Finasteride Trials

Minoxidil and finasteride are not peptides. They are the approved hair-loss medicines, included so the peptide numbers have a yardstick from trials of the same kind. Oral finasteride 1 mg daily raised vertex hair count by 107 hairs at 1 year and 138 at 2 years against placebo in 1553 men, measured in a fixed 5.1 cm2 area (PMID 9777765). Topical minoxidil at 5 percent beat 2 percent and placebo on nonvellus hair count in 393 men over 48 weeks, with about 45 percent more regrowth than 2 percent, at the cost of more scalp irritation (PMID 12196747). Both were randomised, double-blind and placebo-controlled. The hair loss guide covers the causes and diagnosis these medicines are prescribed against, and the collagen peptides guide covers a separate protein often asked about for hair and skin.

The Trial Regimens

The regimens those studies administered, each named with its paper:

GHK peptide with 5-aminolevulinic acid (ALAVAX) at 100 mg/mL or 50 mg/mL, applied topically once daily for 6 months in the hair count trial (PMID 27489425). Topical minoxidil at 5 percent or 2 percent, applied twice daily for 48 weeks in the comparator trial (PMID 12196747). Finasteride 1 mg by mouth once daily in the comparator trials (PMID 9777765).

Disclaimer: these are trial arms reported for comparison, not recommendations and not a titration schedule. Each was administered inside a study, and finasteride and minoxidil are regulated medicines whose use is a clinical decision. The mouse and ex vivo rows carry no human dose and none is implied.

How These Records Were Found

Each line states a query, an index and a date. A search result describes what a string matched in one database on one day, and nothing beyond that.

copper tripeptide AND hair in PubMed on 9 August 2026 returned 8 records, among them PMID 17703734 and PMID 39449909.
GHK-Cu AND hair growth in PubMed on 9 August 2026 returned 5 records; the GHK-Cu string is mapped by PubMed to the glycyl-histidyl-lysine supplementary concept.
copper peptide AND alopecia in PubMed on 9 August 2026 returned 6 records.
biotinyl-GHK in PubMed on 9 August 2026 returned 0 records, and biotinoyl AND tripeptide AND hair returned 0 records; those exact strings matched nothing on that day.
PTD-DBM AND hair in PubMed on 9 August 2026 returned 2 records; the competing-peptide origin study PMID 28595998 was reached through CXXC5 AND peptide AND hair regrowth, which returned 2 records.
thymosin beta 4 AND hair follicle in PubMed on 9 August 2026 returned 12 records, among them PMID 26083021 and PMID 22402437.
For the comparators, finasteride AND randomized AND male pattern hair loss returned 153 records and minoxidil 5 percent AND randomized AND androgenetic alopecia returned 192 records; the landmark trials PMID 9777765 and PMID 12196747 were retrieved from those sets.
A compound name bounds a search, so synonyms and mechanism terms were paired where known: GHK-Cu with glycyl-histidyl-lysine and copper tripeptide, which surfaced the AHK-Cu follicle study, and PTD-DBM with its CXXC5-Dishevelled mechanism term.

Frequently Asked Questions

What are the best peptides for hair growth?+

This page does not rank them. It reports what each cited study looked at, what it measured and what it found, so a placebo-controlled trial in 45 men and a signalling study in transgenic mice can be told apart. Read the population column first: it says whether a result came from people, from human tissue in a dish, or from mice.

Which of these hair results were measured in people?+

Among the human records cited here, a GHK peptide combined with 5-aminolevulinic acid was tested against placebo in 45 men with male pattern hair loss (PMID 27489425), a copper tripeptide-1 scalp serum regimen was tracked open-label without a control group (PMID 39449909), and a copper tripeptide raised hair follicle growth in cultured human tissue (PMID 17703734). The PTD-DBM and thymosin beta-4 results were measured in mice, with some supporting work in human cells. The design column on each row says which is which.

How do the peptide numbers sit next to minoxidil and finasteride?+

The comparator trials were large and long. Topical minoxidil enrolled 393 men over 48 weeks (PMID 12196747) and oral finasteride enrolled 1553 men over 1 to 2 years (PMID 9777765), both randomised, double-blind and placebo-controlled, both measuring scalp hair counts. The GHK peptide trial enrolled 45 men over 6 months (PMID 27489425). The sizes, follow-up and endpoints differ, so each result belongs to the population and design in its own row.

What is PTD-DBM and where was it studied?+

PTD-DBM is a peptide that blocks CXXC5 from binding Dishevelled, which releases the Wnt/beta-catenin pathway involved in hair follicle growth. In the origin study it accelerated hair regrowth and wound-induced follicle neogenesis in mice while CXXC5 was found raised in human balding scalp (PMID 28595998), and a later mouse study linked the same axis to DHT and prostaglandin D2 driven hair loss (PMID 36831222). The compound background differs from copper peptides; see the GHK-Cu page for that molecule.

Are copper peptides, GHK-Cu and AHK-Cu the same thing?+

They are related but not identical. GHK-Cu is glycyl-histidyl-lysine bound to copper. The follicle study on this page used AHK-Cu, an alanyl-histidyl-lysine copper variant (PMID 17703734), and the scalp serum study listed copper tripeptide-1 among several ingredients (PMID 39449909). Background on the molecule sits on the GHK-Cu and topical GHK-Cu pages.

What doses did these trials actually use?+

Reported as trial figures, each named with its paper: GHK peptide with 5-aminolevulinic acid (ALAVAX) at 100 mg/mL or 50 mg/mL, applied topically once daily for 6 months (PMID 27489425). Topical minoxidil at 5 percent or 2 percent, applied twice daily for 48 weeks (PMID 12196747). Finasteride 1 mg by mouth once daily (PMID 9777765). Disclaimer: these are trial arms reported for comparison, not recommendations and not a titration schedule. Each was given inside a study, and a prescription medicine like finasteride is a clinical decision.

Can these regrow hair on their own, without a doctor?+

Hair loss has causes that are diagnosed and managed with a clinician, and the pattern, the tests and the cause change what helps. Every regimen above was administered inside a study, two of them prescription medicines used as comparators. The hair loss guide covers causes and diagnosis; take the population and endpoint of a study to a doctor rather than a compound name off a label.

Research And Sources

Every figure above comes from the record its PMID links to, retrieved through NCBI E-utilities on 9 August 2026. The AHK-Cu follicle result comes from PMID 17703734, the GHK peptide hair counts from PMID 27489425, the copper tripeptide-1 serum figures from PMID 39449909, the PTD-DBM mouse results from PMID 28595998 and PMID 36831222, the thymosin beta-4 mouse result from PMID 26083021, and the comparator hair counts from PMID 9777765 and PMID 12196747. The provenance section records what each search returned, rather than the body claiming anything about what does or does not exist.